These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38601287)

  • 1. Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.
    Ye G; Chen P; Liu X; He T; Pivot X; Pan R; Zhou D; Zhu L; Zhang K; Li W; Yang S; Lin J; Cai G; Huang H
    Gland Surg; 2024 Mar; 13(3):374-382. PubMed ID: 38601287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.
    Zhong X; He P; Chen J; Yan X; Wei B; Zhang Z; Bu H; Li J; Tian T; Lv Q; Wang X; Li H; Wang J; Huang J; Suo J; Liu X; Zheng H; Luo T
    Gland Surg; 2022 Jan; 11(1):216-225. PubMed ID: 35242683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
    Wang Y; Xu Y; Liu X; Li C; Wang J; Zhang X; Shao B; Zhang J
    Gland Surg; 2024 May; 13(5):654-662. PubMed ID: 38845840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial.
    Wang W; Zhang J; Chang JY; Yao DS; Hu F; Liang YP; Shen Y; Liu YQ; Qi HH; Tong JB; Cai HF
    Gland Surg; 2023 Feb; 12(2):208-214. PubMed ID: 36915823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant pyrotinib plus nab-paclitaxel, doxorubicin, and cyclophosphamide for HER2-positive locally advanced breast cancer: a retrospective case-series study.
    Yao DS; Wang W; Chang JY; Zhang Y; Zhang HW; Xu JX; Cai HF
    Gland Surg; 2021 Dec; 10(12):3362-3368. PubMed ID: 35070896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study.
    Li Q; Wang Y; Zhu M; Gu Y; Tang Y
    Gland Surg; 2021 Dec; 10(12):3389-3402. PubMed ID: 35070899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study.
    Li F; Liang Y; Luo M; Shen J; Zhou T; Liang Y; Tang X; Yuan H; Zeng J
    Front Oncol; 2023; 13():1041111. PubMed ID: 36793595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
    Xuhong J; Qi X; Tang P; Fan L; Chen L; Zhang F; Tan X; Yan W; Zhong L; He C; Liang Y; Ren L; Wang M; Zhang Y; Jiang J
    Oncologist; 2020 Dec; 25(12):e1909-e1920. PubMed ID: 33000490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study.
    Liu L; Zhu M; Wang Y; Li M; Gu Y
    World J Surg Oncol; 2023 Dec; 21(1):389. PubMed ID: 38114991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
    Wu J; Jiang Z; Liu Z; Yang B; Yang H; Tang J; Wang K; Liu Y; Wang H; Fu P; Zhang S; Liu Q; Wang S; Huang J; Wang C; Wang S; Wang Y; Zhen L; Zhu X; Wu F; Lin X; Zou J
    BMC Med; 2022 Dec; 20(1):498. PubMed ID: 36575513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis.
    Mao X; Lv P; Gong Y; Wu X; Tang P; Wang S; Zhang D; You W; Wang O; Zhou J; Li J; Jin F
    Front Oncol; 2022; 12():855512. PubMed ID: 35463365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study.
    Wang H; Li Y; Qi Y; Zhao E; Kong X; Yang C; Yang Q; Zhang C; Liu Y; Song Z
    Front Oncol; 2022; 12():909426. PubMed ID: 35875123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study.
    Yang Y; Jin L; Li Y; Rao N; Gong C; Li S; Wu J; Zhao J; Ding L; Gan F; Zhang J; Feng R; Liu Z; Liu Q
    Chin J Cancer Res; 2024 Feb; 36(1):55-65. PubMed ID: 38455369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    Ding Y; Mo W; Xie X; Wang O; He X; Zhao S; Gu X; Liang C; Qin C; Ding K; Yang H; Ding X
    Oncol Res Treat; 2023; 46(7-8):303-311. PubMed ID: 37302393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
    Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
    Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
    Man X; Huang J; Sun S; Zhou D; Zhang B; Fang S; Zheng F; Li C; Wang X; Huang W; Wang L; He Q; Fu H; Zhang Y; Liu C; Dong L; Zhao X; Xu L; Sun X; Fan B; Song L; Zhou Z; Yu J; Li H
    Clin Transl Med; 2024 May; 14(5):e1687. PubMed ID: 38738791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
    Wang C; Zhou Y; Lin Y; Mao F; Guan J; Zhang X; Shen S; Wang X; Zhang Y; Pan B; Zhong Y; Peng L; Cao X; Yao R; Zhou X; Xu C; Xu Y; Sun Q
    BMC Cancer; 2022 Mar; 22(1):269. PubMed ID: 35287613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
    Shi Q; Qi X; Tang P; Fan L; Chen L; Wang S; Liang Y; Hu Y; Wang M; Ren L; Zhang G; Tan X; Yuan L; Du J; Wu X; Wang M; Che H; Lv P; Chen D; Hu J; Li Q; Zhang Y; Yang K; Zhong Y; Chen C; Zhou Z; Qian L; Zhang J; Ma M; Sun Y; Zhang Y; Jiang J
    MedComm (2020); 2023 Dec; 4(6):e435. PubMed ID: 38077249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients.
    Chen Y; Zhang T; Zhang R; Cao X
    Cancer Biother Radiopharm; 2024 Aug; 39(6):435-440. PubMed ID: 38527247
    [No Abstract]   [Full Text] [Related]  

  • 20. Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study.
    Yin W; Wang Y; Wu Z; Ye Y; Zhou L; Xu S; Lin Y; Du Y; Yan T; Yang F; Zhang J; Liu Q; Lu J
    Clin Cancer Res; 2022 Sep; 28(17):3677-3685. PubMed ID: 35713517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.